Musaffa Logo

Our certifications

Independent proof that every stock and portfolio meets halal standards.

How we screen every stock
METHODOLOGY

How we screen every stock

Our 5-step halal methodology, in 90 seconds.

INDV Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: May 23, 2026

Report Source: 2026 1st Quarter Report

Analyst's Ratings for Indivior Pharmaceuticals, Inc (INDV)

Based on 13 analysts giving stock ratings to Indivior Pharmaceuticals, Inc in the past 3 months

Strong
Sell
SellHoldBuyStrong
Buy
Strong Buy
31
Buy
61
Hold
8
Sell
0
Strong Sell
0
Indivior Pharmaceuticals, Inc

Indivior Pharmaceuticals, Inc. Stock Analysis INDV

United States Health Care Mid Cap Report:
Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The firm provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The company sells its products in the United States and in other selected areas of the world.
Read More

Indivior Pharmaceuticals, Inc (INDV) Chart

Key Statistics of Indivior Pharmaceuticals, Inc (INDV)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$38.09$40.03

Today's Open

$38.46

Volume

1.56M

P/E Ratio (TTM)

23.12

52 Week Range

$13.45$41.00

Market Cap

4.57B

Avg. Volume

1.70M

Dividend Yield

-

Financial Metrics & Statements of Indivior Pharmaceuticals, Inc (INDV)

FAQ's for Indivior Pharmaceuticals, Inc (INDV)

  • According to Musaffa’s Shariah screening methodology, Indivior Pharmaceuticals, Inc (INDV) is currently classified as HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
  • A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Indivior Pharmaceuticals, Inc using these criteria to determine its compliance status.
  • Muslim investors may consider investing in Indivior Pharmaceuticals, Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
  • Musaffa determines the Shariah status of Indivior Pharmaceuticals, Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
  • The Shariah compliance status of Indivior Pharmaceuticals, Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
  • Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
  • You can check the latest Shariah compliance status of Indivior Pharmaceuticals, Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.